Association of oestrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer – a retrospective study-1

<p><b>Copyright information:</b></p><p>Taken from "Association of oestrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer – a retrospective study"</p><p>http://www.biomedcentral.com/1471-2407/7/131</p><p>BMC Cancer 2007;7():131-131.</p><p>Published online 18 Jul 2007</p><p>PMCID:PMC1950511.</p><p></p>ses) and dichotomised levels of ERβ2 mRNA in the ERα + tamoxifen-treated cohort and (B, 7 events in 32 ERβ2 high cases and 14 events in 30 ERβ2 low cases). Unbroken green lines represent cases with high levels of ERβ2, dotted blue lines represent cases with low levels. In C cases from the whole cohort were classed as: high for both protein and mRNA (unbroken green line, 7 events in 32 cases); high for protein, low for mRNA (unbroken grey line, 19 events in 44 cases); low for protein, high for mRNA (dotted unbroken black line, 7 events in 14 cases); or low for both protein and mRNA (dotted blue line, 5 events in 7 cases). In all cases crosses represent censored data and P values are given for Log Rank tests